TUSC2 Gene Therapy to Be Studied for Cellular Resilience
Genprex to present research at a November 2026 conference on whether the therapy can improve cellular stress-response pathways.
Updated on Oct. 28, 2026 in Life Sciences
Live Poll
Should pharmaceutical companies prioritize researching aging processes alongside their existing cancer and diabetes treatment programs?
Genprex is set to present findings on its TUSC2 gene therapy at the Gerontological Society of America 2026 Annual Scientific Meeting in National Harbor, Maryland, on November 4, 2026. This research, conducted in collaboration with Meharry Medical College, explores the potential of the therapy to influence cellular resilience and mitochondrial biology.
Why it matters
The research signals a potential pivot for the therapeutic agent REQORSA, which is being studied for biological impacts that extend beyond its primary application in oncology. By investigating stress-response pathways, the collaboration aims to determine if the therapy can be adapted for broader anti-aging and cellular health applications.
The study uses Abstract ID 2489375 to detail the molecular impacts of TUSC2 therapy. Researchers are measuring cellular resilience and mitochondrial metabolic activity, shifting the focus from previous tumor-suppression benchmarks to stress-response pathways.
The players
Genprex
An Austin-based clinical-stage gene therapy company focused on oncology using its REQORSA delivery platform.
Meharry Medical College
A Nashville-based academic health sciences center conducting foundational research into TUSC2 biology.
Mark S. Berger
The Chief Medical Officer of Genprex who oversees the company's clinical research and therapeutic development.
The details
The research investigates the function of the TUSC2 gene—a tumor suppressor gene—in the context of general cellular health. By utilizing REQORSA, a proprietary gene therapy platform that uses a lipid nanoparticle to deliver genetic material into cells, the team at Meharry Medical College is examining how increased TUSC2 expression modulates mitochondria, the energy-producing organelles of the cell, and overall molecular stress responses. This mechanism is being evaluated to see if it triggers a program of cellular resilience, which may improve how cells manage the damage associated with aging.
Timeline
Genprex established its research collaboration with Meharry Medical College in 2024.
The Gerontological Society of America 2026 Annual Scientific Meeting occurs November 4-7, 2026.
The TUSC2 presentation is scheduled for Wednesday, November 4, 2026, from 6:00 to 7:15 p.m. ET.
The Tech Race
This research marks a significant departure from the REQORSA oncology clinical trials by shifting focus from cancer cell suppression to general cellular resilience mechanisms. It represents a strategic effort to validate the therapeutic platform for broader use in aging-related molecular interventions.
The findings from the GSA poster are expected to be published on the Genprex website following the November 4 presentation. This research remains in the discovery phase and does not represent a clinically available therapy for public use at this time.
The takeaway
The research highlights a shift in focus for gene therapy toward broader metabolic applications in aging. Observers should track the Genprex website for the post-conference release of the abstract data to determine the next milestones for the TUSC2 program.
Further reading
For broader insights into genetic research, visit the Life Sciences section.
Source note: This article includes information reported by Star Local.
Live Poll
Should pharmaceutical companies prioritize researching aging processes alongside their existing cancer and diabetes treatment programs?
